31, from 77.7 billion yen, or 107 yen, a year earlier, the maker of the Benicar hypertension medicine said in a statement to the Tokyo Stock Exchange today. ...
*Azor is a trademark of Daiichi Sankyo, Inc.; Benicar and Benicar HCT are registered trademarks of Daiichi Sankyo, Inc.; and Campral is a registered ...
Offerings include Lexapro, for the treatment of depression, Namenda for Alzheimer's disease, Benicar for hypertension, and Campral for the maintenance of ...
Forest also said it will complete its co-promotion deal for the high blood pressure drug Benicar at the end of the fiscal year and will reallocate the sales ...
Other income, which includes contract revenue from the high blood pressure drugs Benicar and Benicare HCT, totaled $80.1 million.
... earnings contribution of $51753000 from the co-promotion of Benicar(R)* (olmesartan medoxomil) and Benicar HCT(R), antihypertensive therapies, ...
... from $250.3 million, or 78 cents a share, a year earlier, helped in part by the co-promotion of antihypertensive therapies Benicar and Benicar HCT. ...
Forest also said it will complete its co-promotion deal for the high blood pressure drug Benicar at the end of the fiscal year and will reallocate the sales ...
Other products include Benicar and Campral. Benicar is used in the treatment of hypertension. Campral is for the maintenance of abstinence from alcohol in ...
Also included in the revenues were earnings contribution of $51.8 million from the co-promotion of Benicar and Benicar HCT, antihypertensive therapies, ...